NEW DELHI, Oct. 9 -- The Delhi High Court on Thursday refused to stop Natco Pharma from selling its generic version of Risdiplam, dismissing a plea by F. Hoffmann-La Roche.

The Swiss drugmaker markets Risdiplam in India as Evrysdi, which is used to treat spinal muscular atrophy (SMA), a rare genetic disorder that causes progressive muscle weakness. Roche had filed the lawsuit in early 2024 after learning of Natco's plans to launch a lower-cost generic version.

A division bench comprising justices C. Hari Shankar and Ajay Digpaul upheld a March 2025 single-judge bench order that had denied Roche an injunction. The single bench had cited public interest, noting that SMA is a rare disease and that wider access to an affordable drug would b...